Non-muscle invasive bladder cancer (NMIBC) grade is a major determinant of progression risk. The most widely utilised grading systems are the World Health Organization (WHO) 1973 and 2004 schemes. Recent publications suggest the utility of combining both into a four-tier or a hybrid three-tier system, subdividing WHO 2004 high grade into two separate categories while […]
Genome-wide association studies (GWAS) of late hematuria following prostate cancer radiotherapy identified single nucleotide polymorphisms (SNPs) near AGT, encoding angiotensinogen. We tested the hypothesis that patients taking angiotensin converting enzyme inhibitors (ACEi) have a reduced risk of late hematuria.
Immune checkpoint inhibitors are an important therapeutic option for urothelial carcinoma, but durable responses are achieved in a minority of patients. Identifying pre-treatment biomarkers that may predict response to these therapies or who exhibit intrinsic resistance, is of paramount importance.
For over 40 years, the gold standard treatment for non-muscular invasive bladder cancer (NMIBC) has been repeated administration of Mycobacterium bovis bacille Calmette-Guerin (BCG). Upon administration, BCG initiates a cascade of immunological events that lead to the recruitment of immune cells to the bladder that eliminates NMIBC cells in a multi-mechanistic, yet incompletely defined manner.
Cancer staging data from the nationwide cancer databases are widely used by researchers to evaluate the efficacy of treatment and propose new strategies for disease management. To make appropriate conclusions, the accuracy of this data is paramount. Tumor registries at individual institutions review patient records to abstract data, which ultimately is incorporated into national cancer […]
Muscle-invasive bladder cancer (MIBC) is associated with a high risk of developing pelvic recurrence. Although adjuvant external beam radiotherapy (EBRT) decreases the risk of local recurrence, it has been associated with severe toxicity. Previous trials that assessed toxicity applied older techniques of delivering EBRT. It is unclear if modern techniques of EBRT delivery, combining highly […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute in Boston. I am so excited to have here with me today, a good friend and colleague, Dr. Elizabeth Plimack, who is the Chief of the Division of GU Medical Oncology and a Professor in the Department […]
To date, there are a relative lack of data on mid-urethral sling (MUS) outcomes among Latina women despite evidence supporting higher rates of urinary incontinence in this ethnic group.1,2 Furthermore, prior studies have demonstrated lower rates of anti-incontinence surgeries among non-white women.3 We previously studied the diversity of patients included in the studies used to […]
Neha Maithel: Welcome everyone to this presentation. We’re going to be talking about imaging in prostate cancer with the F-18 Axumin PET. So my name is Neha Maithel, I’m an Assistant Professor at the University of Texas Health Science Center at Houston. I’m part of the Division of Hematology and Oncology. Next slide. So prostate […]
Currently, the impact of previous, simultaneous, or subsequent bladder cancer on the prognosis of upper urinary tract urothelial carcinoma (UTUC) is controversial. We aimed to investigate the impact of previous, simultaneous or intravesical recurrence (IVR) bladder cancer on the prognosis of UTUC based on a large population-based cohort from the Surveillance, Epidemiology, and End Results […]
